traded as nasdaq bmrn industry biotechnology founded 1997 founders christopher starr glen w. denison jr. headquarters san rafael ca united states key people jean jacques bienaime chief executive officer henry j. fuchs chief medical officer dan spiegelman chief financial officer products kuvan naglazyme aldurazyme firdapse vimizim revenue us 889 million 2015 1 operating income us 171 million 2015 1 total assets us 2.49 billion 2014 1 total equity us 1.52 billion 2014 1 number of employees 2200 2016 2 website www.biomarin.com footnotes references 3 4 biomarin pharmaceutical inc. is a biotechnology company based in san rafael california . it has offices and facilities in the united states south america asia and europe . biomarin s core business and research is in enzyme replacement therapies erts . biomarin was the first company to provide therapeutics for mucopolysaccharidosis type i mps i by manufacturing laronidase aldurazyme commercialized by genzyme corporation . biomarin was also the first company to provide therapeutics for phenylketonuria pku . contents 1 history 2 business development 3 products 4 controversies 5 references history edit biomarin was founded in 1997 by christopher starr ph.d. and grant w. denison jr. with an investment of a 1.5 million from glyko biomedical and went public in 1999 . 5 6 seed investors were amongst others mpm bioventures grosvenor fund and florian sch nharting . 7 business development edit in 2002 biomarin acquired glyko biomedical . 8 in 2009 biomarin acquired huxley pharmaceuticals inc. huxley which had rights to a proprietary form of 3 4 diaminopyridine 3 4 dap amifampridine phosphate . 9 in 2010 biomarin was granted marketing approval by the european commission for 3 4 diaminopyridine 3 4 dap amifampridine phosphate for the treatment of the rare autoimmune disease lambert eaton myasthenic syndrome lems . biomarin launched the product under the name firdapse . 10 in 2010 biomarin acquired lead therapeutics inc. lead a small private drug discovery and early stage development company with key compound lt 673 an orally available poly adp ribose polymerase parp inhibitor studied for the treatment of patients with rare genetically defined cancers . 11 this acquisition was followed by the purchase of zystor therapeutics inc. zystor a privately held biotechnology company developing erts for the treatment of lysosomal storage disorders and its lead product candidate zc 701 a fusion of insulin like growth factor 2 and alpha glucosidase igf2 gaa in development for pompe disease . 12 at its r & d day in october 2010 biomarin also announced a new program for a peptide therapeutic vosoritide bmn 111 for the treatment of achondroplasia . 13 in 2012 biomarin acquired zacharon pharmaceuticals a private biotechnology company based in san diego focused on developing small molecules targeting pathways of glycan metabolism . 14 in 2014 biomarin acquired a histone deacetylase inhibitor chemical library from repligen for 2 million with the intention of advancing work toward therapies for friedreich s ataxia and other neurological disorders . 15 in november 2014 the company agreed the acquisition of prosensa for up to 840 million 16 the range of treatments for duchenne muscular dystrophy however failed to attain fda approval and in may 2016 development ceased . 17 products edit as of 2016 biomarin has five products on the market each of which is an orphan drug . 18 tetrahydrobiopterin branded as kuvan sapropterin dihydrochloride a small molecule drug for phenylketonuria introduced in 2007 as the first medication based intervention to treat phenylketonuria 19 arylsulfatase b branded as naglazyme galsulfase a recombinant protein therapeutic for maroteaux lamy syndrome also called mucopolysaccharidosis type vi iduronidase branded as aldurazyme a recombinant protein therapeutic for mucopolysaccharidosis i amifampridine branded as firdapse a small molecule drug for lambert eaton myasthenic syndrome as of 2013 approved in the eu only elosulfase alfa branded as vimizim is the only enzyme replacement therapy to address the cause of morquio a syndrome mps iva which affects an estimated 3 000 patients in the developed world . the disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan gag metabolism . controversies edit in 2010 biomarin became involved in controversy 20 21 surrounding 3 4 diaminopyridine 3 4 dap . biomarin markets a phosphate salt of 3 4 dap under the name firdapse . in 2010 biomarin was granted exclusive licensing rights to firdapse for 10 years . as a result the price of a prescribed national health service treatment course has increased from 1 987 for the unlicensed drug to 69 970 for firdapse . the company states that prior to its licensing there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process . 22 in 2013 biomarin pharmaceuticals was at the center of a high profile debate regarding expanded access of cancer patients to experimental drugs . 23 on the advice of her doctor andrea sloan a patient with advanced ovarian cancer requested that the company provide her with access to bmn 673 an unapproved parp inhibitor drug candidate that had exhibited promising activity in a small phase 1 clinical trial . the company declined citing safety concerns . 24 ms. sloan eventually received a similar drug candidate from a different company . 25 in 2015 there was another controversy over expanded access concerning the supply of a drug on clinical trial to a german child who was suffering from a brain disorder but who was not part of the trial . 26 references edit use yyyy mm dd format for publication dates a b c d biomarin pharmaceutical 2014 annual report form 10 k xbrl . united states securities and exchange commission . march 2 2015 . biomarin pharmaceutical 2015 03 02 . 2014 form 10 k annual report . sec . retrieved 2015 03 05 . biomarin pharmaceutical bmrn annual sec income statement filing via wikinvest . biomarin pharmaceutical bmrn annual sec balance sheet filing via wikinvest . biomarin . life sciences at chf . retrieved 2016 07 09 . history . www.biomarin.com . biomarin . retrieved 2016 07 09 . self published source form s 1 registration statement . biomarin pharmaceuticals inc. retrieved 15 december 2015 . biomarin pharmaceutical acquires glyko biomedical . deals . lexpert . thomson reuters . january 2003 . archived from the original on 2013 12 28 . stevens loralee 2009 10 27 . biomarin acquires huxley pharmaceuticals . north bay business journal . santa rosa california united states . archived from the original on 2011 01 04 . retrieved 2014 02 18 . biomarin launches lems drug firdapse in european union ; and genmab gets conditional approval for arzerra . the pharma letter . 2010 04 20 . retrieved 2014 02 18 . subscription required brown steven e.f. 2010 02 04 . biomarin to buy lead therapeutics for 18m . san francisco business times . archived from the original on 2011 06 29 . retrieved 2014 02 18 . leuty ron 2010 08 17 . biomarin to buy zystor for up to 115m . san francisco business times . archived from the original on 2011 06 29 . retrieved 2014 02 18 . andersen karen 2010 10 21 . biomarin highlights diverse early stage pipeline at r & d day . morningstar . retrieved 2011 02 14 . brown steven 2013 01 07 . biomarin pharmaceutical buys zacharon for 10 million . san francisco business times . retrieved 2013 01 07 . biomarin nabs repligen s hdaci compound library . news discovery & development . gen. eng . biotechnol . news paper . 34 4 . 15 february 2014 . p. 14 . http www.genengnews.com gen news highlights biomarin to acquire prosensa for up to 840m 81250633 biomarin announces withdrawal of market authorization application for kyndrisa drisapersen in europe nasdaq bmrn . investors.bmrn.com . retrieved 2016 07 04 . biomarin office site products pollack a 2007 12 14 . agency approves drug to treat genetic disorder that can lead to retardation . the new york times . retrieved 2008 04 03 . goldberg adrian 2010 11 21 . drug firms accused of exploiting loophole for profit . bbc news . retrieved 2010 11 21 . martin daniel 2010 09 27 . hospitals are forced to use unlicensed medicines to save millions . daily mail . london . retrieved 2010 11 21 . what makes an orphan drug . british medical journal . 2010 11 10 . retrieved 2010 11 21 . andrea sloan faces pharma firm with history of indifference . huffington post . 2013 09 26 . retrieved 2013 12 24 . in cancer drug battle both sides appeal to ethics . cnn . 2013 09 20 . retrieved 2013 12 24 . ed silverman for pharmalot . october 4 2013 andrea sloan poster child for compassionate use gets a drug hannahs kampf gegen pharmafirma . b5 aktuell . 2015 05 13 . retrieved 2015 05 13 . v t e companies of the nasdaq 100 index 21st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazon.com american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu bed bath & beyond biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cisco systems citrix systems cognizant comcast costco csx ctrip.com international discovery communications dish network dollar tree ebay electronic arts endo international expedia express scripts facebook fastenal fiserv gilead sciences henry schein illumina incyte intel intuit intuitive surgical jd.com kraft heinz lam research liberty braves liberty global liberty interactive liberty media linear technology marriott international mattel maxim integrated products micron technology microsoft mondelez international monster beverage mylan netapp netflix norwegian cruise line holdings nvidia nxp semiconductors o reilly automotive paccar paychex paypal qualcomm regeneron ross stores sandisk sba communications seagate technology sirius xm holdings skyworks solutions starbucks stericycle symantec t mobile us tesla motors texas instruments the priceline group tractor supply company tripadvisor ulta salon cosmetics & fragrance verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital whole foods market xilinx yahoo retrieved from https en.wikipedia.org w index.php title biomarin pharmaceutical & oldid 729131930 categories companies in the nasdaq 100 indexcompanies in the nasdaq biotechnology indexbiotechnology companies of the united statescompanies listed on nasdaqnovato californiatechnology companies based in the san francisco bay areapharmaceutical companies established in 1997orphan drug companieslife sciences industryhidden categories accuracy disputes from july 2016pages containing links to subscription only content navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages fran ais edit links this page was last modified on 10 july 2016 at 03 33 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view